Gland Pharma inks CDMO deal with global co. for $90-100M revenue potential

Gland Pharma Limited has announced the execution of a strategic Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company. This partnership positions Gland Pharma as an integrated end-to-end CDMO partner for a portfolio of sterile injectable products, including both commercially marketed and pipeline products. The collaboration follows a full-service CDMO model, encompassing technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply. The product portfolio includes oncology and non-oncology products in various presentations such as vials, lyophilized forms, ampoules, and pre-filled syringes. Gland Pharma will utilize its integrated capabilities to offer a comprehensive "one-stop" solution. The agreement is projected to offer strong long-term business visibility, with revenue generation expected to commence from calendar year 2029. Initially, the agreement covers 55 Stock Keeping Units (SKUs) to be manufactured across three Gland Pharma sites, with potential for additional products soon. Upon full commercialization, the annualized revenue potential is estimated to be approximately USD 90-100 million (approximately ₹750-830 crore). Technology transfer activities are slated for completion within two years. Mr. Srinivas Sadu, Executive Chairman, Gland Pharma Limited, expressed pleasure in entering this strategic collaboration, highlighting the confidence global companies have in Gland Pharma's capabilities and emphasizing the agreement's contribution to long-term revenue visibility and expansion of the CDMO business.